BNET Industries
Last Fiscal Year Sales:$1.0B
- Private
- US
Dow Jones Description
Injectable Monoclonal Antibody-Based Pharmaceuticals Mfr & Developer for Cardiovascular, Infectious & Autoimmune Diseases
CFO & Vice President
Richard A. BierlyNumber of Employees 3,000
Peer Companies
NAICS Code In-Vitro Diagnostic Substance Manufacturing: 325413
Recent Events
-
Litigator of the Week: Dianne Elderkin of Woodcock Washburn
News & Analysis
Filter by
centocor inc. and peptech ltd. - All News and Analysis
SHARES IN AUSTRALIA'S PEPTECH SOAR AFTER NEW PROFIT GUIDANCE.
MELBOURNE, Nov 16 Asia Pulse - Shares in biotech Peptech Ltd (ASX:PTD) jumped almost 30 per cent in early trading today after releasing new profit guidance in the wake of settling a long-running licence dispute with Centocor. Peptech expects a net profit after tax for the year ending...
AUSTRALIAN BIOTECH PEPTECH LISTS PRIORITIES FOR 2004.
SYDNEY, Jan 14 Asia Pulse - Cancer therapies, anti-inflammatory drugs and a contraceptive for the household pet are at the top of the priority list in 2004 for Australian biotech Peptech Ltd (ASX:PTD). Peptech has vowed to put behind it two high profile patent disputes and concentrate on...
AUSTRALIA'S PEPTECH WARNS US MAY APPLY DRUG WARNING TO PRODUCTS.
MELBOURNE, March 6 Asia Pulse - Australian biotech Peptech Ltd (ASX:PTD) said today that United States regulators were considering labelling some arthritis drugs to warn they could increase the risk of cancer. But the company, which holds several patents for proteins used in anti-arthritis drugs, said major US...
AUSTRALIA'S PEPTECH SHARES PLUNGE 25% AFTER DISPUTE ANNOUNCEMENT.
MELBOURNE, Feb 19 Asia Pulse - Shares in biotech Peptech Ltd (ASX:PTD) plunged 25 per cent yesterday after the company announced yesterday a patent dispute with United States firm Centocor Inc had not been resolved. Peptech shares fell 43 cents to A$1.29, after slumping to an intraday low...
AUSTRALIA'S PEPTECH, US CENTOCOR PATENT DISPUTE RAVAGES SHARES.
MELBOURNE, Feb 18 Asia Pulse - Shares in biotech Peptech Ltd (ASX:PTD) dived 27 per cent in early trading today after the company announced overnight that a patent dispute with United States firm Centocor Inc had not been resolved. At 1012 AEDT, Peptech was 47 cents, or 27.33...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Richard A. Bierly | CFO & Vice President |
| Daniel Everitt | Vice President of Clinical Pharmacology and Global Pharmacovigilance |
| Ronald E. Schmid | Vice President, Corp Communications |
| William R Tolbert | Vice President |
| David P. Holveck | Director |
| Organization | Position | Status |
|---|---|---|
| Centocor, Inc. | CFO & Vice President | Current |
| Organization | Position | Status |
|---|---|---|
| Centocor, Inc. | Vice President of Clinical Pharmacology and Global Pharmacovigilance | Current |
| Institute for Oneworld Health | Board of Directors | Current |
| SmithKline Beecham Corporation | Director of Clinical Pharmacology | Former |
| Neuroscience, Inc | Group Director | Former |
| Organization | Position | Status |
|---|---|---|
| Centocor, Inc. | Vice President, Corp Communications | Current |
| Organization | Position | Status |
|---|---|---|
| Advanced Tissue Sciences, Inc. | Vice President | Current |
| Centocor, Inc. | Vice President | Current |
| Invitron Limited | Vice President | Current |
| Merchant-Taylor International, Inc | Senior Associate | Current |
David P. Holveck was appointed President, Chief Executive Officer, and a Director of Endo in April 2008. Prior to joining Endo, Mr. Holveck was President of Johnson & Johnson Development Corporation and Vice President, Corporate Development of Johnson & Johnson since 2004. Mr. Holveck joined Johnson & Johnson as a company Group Chairman in 1999, following the acquisition of Centocor, Inc., by Johnson & Johnson. Mr. Holveck was Chief Executive Officer of Centocor, Inc., at the time of the acquisition. Mr. Holveck joined Centocor in 1983 and progressed through various executive positions. In 1992, he assumed the role of President and Chief Operating Officer and later that year was named President and Chief Executive Officer. Prior to joining Centocor, he held positions at General Electric Company, Corning Glass Works, and Abbott Laboratories. Mr. Holveck is a member of the Board of Trustees for the Fund for West Chester University and the Board of Directors of the Eastern Technology Council as well as the Board of Directors of Light Sciences Oncology, Inc.
| Organization | Position | Status |
|---|---|---|
| Endo Pharmaceuticals Holdings Inc. | President & Chief Executive Officer | Current |
| Johnson & Johnson Development Corp. | Vice President, Corporate Development | Current |
| Tengion, Inc. | Current | |
| Biotechnology Industry Organization | board member | Current |
| Eastern Technology Council | Board Member | Current |
| Centocor, Inc. | Director | Current |
| University City Science Center | Board of Directors | Current |
| Light Sciences Oncology, Inc. | Board of Directors | Current |
| Liberty Science Center, Inc. | Board Member | Current |
| Endo Pharmaceuticals Holdings Inc. | Board of Directors | Current |
| Centocor, Inc. | Chief Executive Officer | Former |
| Johnson & Johnson | President, Corporate Development | Former |
| Centocor, Inc. | president | Former |
| Centocor, Inc. | chief operating officer | Former |
| General Electric Company | Team Member | Former |
| Abbott Laboratories | Team Member | Former |
| Corning Glass Works | Team Member | Former |
| Johnson & Johnson Development Corp. | President | Former |
| The Group Inc. | Chairman | Former |
| Johnson & Johnson Development Corp. | Company Group Chairman | Former |
| Johnson & Johnson | Company Group Chairman | Former |
| West Chester University | B.S. Degree In Education | Former |
Executive News
-
Endo Pharmaceuticals Introduces Valstar (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer
-
FDA extends review on Endo drug
-
Endo Pharmaceuticals (ENDP) Says FDA Extends Review Date for Testosterone Treatment 9/3/2009
-
Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive...
-
Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer
-
Endo Pharmaceuticals Gives Update on Regulatory Status of Testosterone Undecanoate...
-
Endo Pharmaceuticals Gives Update on Regulatory Status of Testosterone Undecanoate for Men with Hypogonadism
-
FDA taking more time to review Endo hypogonadism drug
-
Endo partners with ProStrakan to market testosterone transdermal gel
-
Endo to commercialize Fortesta in the U.S.
-
Endo licenses ProStrakan's testosterone gel Fortesta in US for up to $210 million
-
Endo buys rights to ProStrakan testosterone replacement gel Fortesta
-
Endo In Deal To Sell ProStrakan's Testosterone Gel In US
-
Endo Pharmaceuticals to Partner With ProStrakan to Commercialize FORTESTA(TM) in the U.S.
-
Biotech 2009 to Feature Endo Pharmaceuticals President and CEO, David P. Holveck, as Dinner...
-
Endo Pharmaceuticals's COO resigns
-
Endo Pharmaceuticals (ENDP) Announces Resignation of Chief Operating Officer
-
Endo Pharmaceuticals Announces Resignation of Chief Operating Officer
-
Endo Pharmaceuticals Announces Resignation of Chief Operating Officer
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
Glass Door
Centocor
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes

